Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DiscoveRx Expands its GPCR Technology Portfolio to Include Advanced Technologies

Published: Friday, April 09, 2010
Last Updated: Friday, April 09, 2010
Bookmark and Share
Introduces two additional GPCR platforms to facilitate counterscreening, lead optimization and SAR evaluation of compounds.

DiscoveRx continues to innovate in the field of GPCR signaling assays, tools and services with the introduction of two additional GPCR platforms to facilitate counterscreening, lead optimization and SAR evaluation of compounds identified during a primary screen.

Endocytosis is fundamental to GPCR biology, regulating the amount of cell-surface receptors, helping to transduce signals from the receptor and controlling the recycling or degradation of the receptor itself. Therefore, quantitative analysis of the internalization kinetics of the receptor from the cell surface can lead to the discovery of novel compounds with unique attributes.

The PathHunter™ Activated GPCR Internalization technology is a non-imaging, non-antibody based platform that provides a direct and quantitative measurement of internalized GPCR localized to intracellular endosomes allowing the fate of unlabeled, activated GPCRs to be monitored in live cells. Unlike other traditional internalization technologies, PathHunter™ Assays are simple, non-radioactive chemiluminescent assays that are ideal for studying GPCR receptor recycling and kinetics, determining mechanism of action of lead compounds or identifying novel inhibitors of receptor internalization.

The PathHunter™ ß-Arrestin Ortholog GPCR assays are fully validated, functional clonal cell lines expressing ortholog GPCRs that have been optimized to detect a full range of compound pharmacologies. With a portfolio of more than 80 ortholog GPCR targets, drug discovery researchers can gain a greater understanding of putative leads, determine mechanism of action, or delineate differential ligand-activated responses of lead compounds prior to testing in expensive animal models.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Validation of Drug Toxicity Prediction using DiscoveRx Model
BioMAP® Systems was shown to identify important safety aspects of drugs and chemicals more efficiently and accurately than can be achieved by animal testing.
Tuesday, May 20, 2014
DiscoveRx Corporation Acquires Bioseek
DiscoveRx adds primary cell assays to its portfolio of drug discovery solutions.
Thursday, November 08, 2012
DiscoveRx Corporation Continues to Innovate with Solutions for Epigenetic Drug Discovery Programs
The company announced availability of platform for studying Bromodomains, an emerging class of epigenetic targets.
Monday, February 06, 2012
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Known Genetic Risk Factors for Endometrial Cancer Doubles
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!